{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"28.7","value":"11.8"},{"groupId":"OG001","lowerLimit":"10.5","upperLimit":"26.0","value":"16.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo observation until disease progression.","id":"OG000","title":"Arm A (Observation)"},{"description":"Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.","id":"OG001","title":"Arm B (Pemetrexed)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}